Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Carol S Lim"'
Autor:
Jonathan E Constance, Mary M McFarland, Tallie Casucci, Michael W Deininger, Elena Y Enioutina, Kathleen Job, Richard S Lemons, Carol S Lim, Robert M Ward, Venkata Yellepeddi, Kevin M Watt
Publikováno v:
JMIR Research Protocols, Vol 12, p e38167 (2023)
BackgroundNumerous reports contend opioids can augment or inhibit malignancy. At present, there is no consensus on the risk or benefit posed by opioids on malignancy or chemotherapeutic activity. Distinguishing the consequences of opioid use from pai
Externí odkaz:
https://doaj.org/article/01de88bf0bb141f3bfea67eaff1c11ed
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53272 (2013)
Mitochondrial targeting of antioxidants has been an area of interest due to the mitochondria's role in producing and metabolizing reactive oxygen species. Antioxidants, especially vitamin E (α-tocopherol), have been conjugated to lipophilic cations
Externí odkaz:
https://doaj.org/article/9420a86b35d44b9a9d6c6086bf810e80
Autor:
Katherine E. Redd Bowman, Lisa Ahne, Liam O’Brien, Erica R. Vander Mause, Phong Lu, Bryce Wallis, Kimberley J. Evason, Carol S. Lim
Publikováno v:
Molecular Pharmaceutics. 20:331-340
With few curative treatments and a global yearly death rate of over 800,000, hepatocellular carcinoma (HCC) desperately needs new therapies. Although wild-type p53 gene therapy has been shown to be safe in HCC patients, it has not shown enough effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03163c3e4ecbbcfe3a46ba33865723c3
https://doi.org/10.1021/acs.molpharmaceut.2c00665
https://doi.org/10.1021/acs.molpharmaceut.2c00665
Publikováno v:
Trends in Biotechnology. 40:875-890
Chimeric antigen receptor (CAR) T cells have revolutionized cancer treatment. CARs use antibody-derived binding domains to redirect T cells to antigens expressed on the surface of cancer cells. However, the high affinity of most currently used CAR-bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d23103911e51cf65be3b30fe92a0c0
https://doi.org/10.1016/j.tibtech.2021.12.009
https://doi.org/10.1016/j.tibtech.2021.12.009
Autor:
Jonathan E Constance, Mary M McFarland, Tallie Casucci, Michael W Deininger, Elena Y Enioutina, Kathleen Job, Richard S Lemons, Carol S Lim, Robert M Ward, Venkata Yellepeddi, Kevin M Watt
BACKGROUND Numerous reports contend opioids can augment or inhibit malignancy. At present, there is no consensus on the risk or benefit posed by opioids on malignancy or chemotherapeutic activity. Distinguishing the consequences of opioid use from pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c9c9ff27eaa98192fc39b94251659bb
https://doi.org/10.2196/preprints.38167
https://doi.org/10.2196/preprints.38167
Publikováno v:
Therapeutic Delivery. 11:833-850
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death globally, mainly due to lack of effective treatments – a problem that gene therapy is poised to solve. Successful gene therapy requires safe and efficient delivery vector
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ef01aefe814830281d868ea2b30ac1
https://doi.org/10.4155/tde-2019-0076
https://doi.org/10.4155/tde-2019-0076
Publikováno v:
Biomolecules. 13:159
It has been well established that mutations in the tumor suppressor gene, p53, occur readily in a vast majority of cancer tumors, including ovarian cancer. Typically diagnosed in stages three or four, ovarian cancer is the fifth leading cause of deat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65ee17dd14da1386a0e1a6d0a2835f1d
https://doi.org/10.3390/biom13010159
https://doi.org/10.3390/biom13010159
Autor:
Erica R. Vander Mause, Jillian M. Baker, Kenneth A. Dietze, Sabarinath V. Radhakrishnan, Thierry Iraguha, Patricia Davis, Jens Panse, James E. Marvin, Michael L. Olson, Mary Steinbach, David P. Ng, Carol S. Lim, Djordje Atanackovic, Tim Luetkens
T cells expressing chimeric antigen receptors have shown remarkable therapeutic activity against different types of cancer. However, their wider use has been hampered by the potential for life-threatening toxicities due to the unintended targeting of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::173e2d1c50b19b87a441aae42b86bd0f
https://doi.org/10.1101/2021.12.06.471279
https://doi.org/10.1101/2021.12.06.471279
Autor:
Andrew S. Dixon, Carol S. Lim
Publikováno v:
BioTechniques, Vol 49, Iss 1, Pp 519-524 (2010)
Protein interactions are critical for normal biological processes and molecular pathogenesis. While it is important to study these interactions, there are limited assays that are performed inside the cell, in the native cell environment, where the ma
Externí odkaz:
https://doaj.org/article/cb21a2bcf828414d91381740d6c285ce
Autor:
Sarah M. Brown, Erica R. Vander Mause, Carol S. Lim, Katherine E Redd Bowman, Madeline Joklik-Mcleod, Phong Lu, Han T N Nguyen
Publikováno v:
Molecular Pharmaceutics. 16:3386-3398
Clinical trials involving p53 gene therapy for ovarian cancer failed due to the dominant negative inhibition of wild-type p53 and multiple genetic aberrations in ovarian cancer. To overcome this problem, we have designed a more potent chimeric gene f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c4606b9590b32f47934c6f5063aa3c
https://doi.org/10.1021/acs.molpharmaceut.9b00136
https://doi.org/10.1021/acs.molpharmaceut.9b00136